Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 111.02% | 10.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 111.02% | 10.11% | |||
| Cost of Revenue | 35.15% | 47.45% | |||
| Gross Profit | -7.35% | -68.37% | |||
| SG&A Expenses | 9.35% | -2.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.97% | 31.33% | |||
| Operating Income | -7.95% | -38.14% | |||
| Income Before Tax | -9.41% | -40.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.17% | -41.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.17% | -41.00% | |||
| EBIT | -7.95% | -38.14% | |||
| EBITDA | -7.97% | -38.44% | |||
| EPS Basic | -1.01% | -18.94% | |||
| Normalized Basic EPS | -1.25% | -18.66% | |||
| EPS Diluted | -1.01% | -18.94% | |||
| Normalized Diluted EPS | -1.25% | -18.66% | |||
| Average Basic Shares Outstanding | 8.07% | 18.56% | |||
| Average Diluted Shares Outstanding | 8.07% | 18.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||